JAMA Psychiatry· 2012Q1· Clinical trial
A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression
- 1,591citations
- Q1SCImago
- 2012year
Short summary
The TNF antagonist infliximab did not show overall efficacy for treatment-resistant depression, but it improved depressive symptoms in patients with high baseline inflammatory biomarkers (hs-CRP > 5 mg/L).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Biological Psychiatry
Biological PsychiatryNeuroscience